Bioresorbable Coronary Stents Market Revenue to Attain USD 641.47 Mn by 2035

Published: 09 Feb 2026

Author: Precedence Research

Share:

Bioresorbable Coronary Stents Market Revenue and Trends 2026 to 2035

The global bioresorbable coronary stents market revenue was valued at USD 357.18 million in 2025 and is expected to attain around USD 641.47 million by 2035, growing at a CAGR of 6.00% during forecast period.The market is growing due to the increasing prevalence of cardiovascular diseases, coupled with the growing preference for minimally invasive interventions that offer temporary vessel support and reduced long-term complications compared with permanent metallic stents.

What are the Major Factors Driving the Growth of the Bioresorbable Coronary Stents Market?

There are numerous factors that are driving the growth of the market for bioresorbable coronary stents. Firstly, the increasing prevalence of coronary artery disease worldwide is boosting the demand for new treatment options that provide restored blood flow to the affected regions without requiring a permanent implant. Secondly, advancements in materials and engineering, such as polymer and magnesium alloy stent platforms, are encouraging greater physician adoption due to their enhanced safety and efficacy.

The shift toward outpatient care and minimally invasive percutaneous coronary interventions (PCI) is supporting the adoption of resorbable stents, enabling faster recovery and shorter hospital stays. Recent technological advances, such as second-generation scaffolds with ultra-thin struts, improved drug-elution, and optimized degradation rates, are enhancing clinician confidence and boosting patient acceptance of these devices.

Segment Insights

• By material, the polymers segment dominated the market in 2025 because polymer-based stents offer superior flexibility, biocompatibility, and controlled degradation, making them safer and more effective for restoring blood flow without permanent implants.
• By drug, the sirolimus segment is the dominant segment in the market due to its ability to inhibit smooth muscle cell growth and limit re-blocking. Its proven safety and efficacy profile has made it the preferred drug for drug-eluting stents, enhancing physician confidence and patient outcomes.
• By end use, the outpatient facilities segment dominated the market with a major revenue share because these settings support minimally invasive percutaneous coronary interventions (PCI), allowing patients to undergo procedures with shorter hospital stays and faster recovery.

Regional Insights

North America led the bioresorbable coronary stents market with the largest share in 2025. This is mainly due to its advanced healthcare system, rapid adoption of interventional technologies, and a high number of ongoing clinical trials. A well-established reimbursement framework and physicians’ interest in innovative PCI devices are expected to sustain the region’s leading position in the market.

Asia Pacific is expected to grow at the fastest rate in the market over the forecast period, driven by a rising prevalence of cardiovascular disease, improved healthcare access, and government incentives supporting stent adoption. Significant investments in medical device manufacturing, along with expanding public health programs and increasing procedure volumes, particularly in China and India, are further boosting market growth in the region.

Bioresorbable Coronary Stents Market Coverage

Recent Developments

• In February 2025, Biotronik initiated the BIOMAG-LL pre-market trial to evaluate its Freesolve® Resorbable Magnesium Scaffold in treating long coronary lesions, expanding clinical evidence and device applicability to more complex patient profiles. (Source- https://www.biotronik.com)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7585

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344